Cytomegalovirus vaccine

A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or curb virus re-activation (symptomatic flare-ups) in persons already infected. Challenges in developing a vaccine include adeptness of CMV in evading the immune system and limited animal models. As of 2018 no such vaccine exists, although a number of vaccine candidates are under investigation. They include recombinant protein, live attenuated, DNA and other vaccines.

As a member of the TORCH complex, cytomegalovirus can cause congenital infection, which can lead to neurological problems, vision and hearing loss. Infection/re-activation of CMV in immuno-compromised persons, including organ transplantation recipients, causes significant mortality and morbidity. Additionally, CMV is implicated in the pathogenesis of various chronic conditions including atherosclerosis and coronary artery disease with recent studies indicating a potential link to increased risk of Alzheimer's disease. Therefore naturally there has been considerable effort made towards the development of a CMV vaccine, with particular emphasis on protection of pregnant women. Development of such a vaccine has been emphasized as a priority by the National Vaccine Program Office in the United States.

Since vaccination of the immunocompromised persons introduces additional challenges, members of this population are less likely to be candidates for such a vaccine.